Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACHA-02: Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases
2025-523913-27-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jun 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival (PFS). Planned start Jun 2026; status: authorised.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-523913-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523913-27-00.